General AML

Guadecitabine in elderly patients with treatment-naïve AML

Hagop M. Kantarjian from The University Texas MD Anderson Cancer Center, Houston, Texas, and Gail J. Roboz, co-chair of our North American Steering Committee from Weill Medical College of Cornell University, New York, et al. reported results from the phase II portion of their randomized multicenter phase I/II study (NCT01261312), which evaluated the safety and efficacy of two doses of guadecitabine (SGI-110), a Hypomethylating Agent (HMA), in treatment-naïve elderly patients (≥ 65 years) with Acute Myeloid Leukemia (AML) who are not eligible for intensive chemotherapy. The results of the study were published ahead of print in The Lancet Oncology on 24th August 2017. 1

Guadecitabine is a next generation HMA dinucleotide of decitabine and deoxyguanosine that is not degraded by cytidine deaminase (an enzyme that degrades decitabine). This allows prolonged exposure of leukemia cells to decitabine, its active metabolite. Findings from the phase I portion of this phase I/II study established 60 mg/m2 guadecitabine as an effective dose and schedule.

In the phase II portion, 107 treatment-naïve AML patients (median age = 77 years, range 62–92) were enrolled between August 24, 2012 and September 15, 2014 and 103 patients were administered subcutaneous guadecitabine in a 28-day cycle. Fifty-one patients were randomly assigned to receive either 60 mg/m2 (n = 24) or 90 mg/m2 (n = 27) guadecitabine on a 5-day schedule. The remaining 52 patients were assigned to receive 60 mg/m2 guadecitabine on a 10-day schedule.  The primary endpoint of the study was composite Complete Response (CR [CR, CR with incomplete platelet recovery, or CR with incomplete neutrophil recovery regardless of platelets]).

The key results of the study were:
  • Composite CR
    • 5-day schedule
      • 60 mg/m2 = 54% (13/24)
      • 90 mg/m2 = 59% (16/27)
    • 10-day schedule
      • 60 mg/m2 = 50% (26/52)
  • Median Overall Survival (OS) in patients in the 5-day and 10-day schedule; 10.5 vs 9.5 months
  • OS was significantly longer in patients who achieved a composite CR compared to non-responders; P < 0.0001
  • Most frequent grade 3 or worse Adverse Events (AEs) regardless of relationship to treatment were febrile neutropenia, thrombocytopenia, neutropenia, pneumonia, anemia, and sepsis
  • Death occurred in 23 patients as a result of AEs including sepsis (n = 8), pneumonia (n = 5), multi-organ failure (n = 2)

The authors emphasized that their study is limited by the small sample size and the absence of randomization against a treatment comparator. They further concluded that the recommended guadecitabine regimen for elderly patients (≥ 65 years) is 60 mg/m2 in a 5-day schedule based on the “absence of any superior activity of the higher dose or longer daily administration”.

Based on the findings of this study, a phase III randomized study (NCT02348489), which aims to assess the safety and efficacy of guadecitabine 60 mg/m2 in a 5-day schedule compared to standard of care is currently underway in previously untreated AML patients.

In an accompanying commentary, Felicetto Ferrara from the Cardarelli Hospital, Naples, Italy, highlighted that the findings of this study shows that “guadecitabine represents a potential new therapeutic option for a challenging disease in older individuals”. 2

Abstract
Background

The hypomethylating drugs azacitidine and decitabine have shown efficacy in myelodysplastic syndromes and acute myeloid leukaemia, but complete tumour responses are infrequent and of short duration, possibly because of the short half-lives and suboptimal bone marrow exposure of the drugs. Guadecitabine, a next-generation hypomethylating drug, has a longer half-life and exposure than its active metabolite decitabine. A phase 1 study established 60 mg/m2 guadecitabine for 5 days as an effective treatment schedule. In this phase 2 study, we aimed to assess the safety and activity of two doses and schedules of guadecitabine in older (≥65 years) patients with treatment-naive acute myeloid leukaemia who were not candidates for intensive chemotherapy.

Methods

We did a multicentre, randomised, open-label, phase 1/2 study of guadecitabine in cohorts of patients with treatment-naive acute myeloid leukaemia, relapsed or refractory acute myeloid leukaemia, and myelodysplastic syndromes; here we report the phase 2 results from the cohort of treatment-naive patients with acute myeloid leukaemia. We included patients aged at least 65 years from 14 US medical centres (hospitals and specialist cancer clinics) who were not candidates for intensive chemotherapy and randomly assigned them (1:1) using a computer algorithm (for dynamic randomisation) to guadecitabine 60 or 90 mg/m2 on days 1–5 (5-day schedule) of a 28-day treatment cycle. Treatment allocation was not masked. We also assigned additional patients to guadecitabine 60 mg/m2 in a 10-day schedule in a 28-day treatment cycle after a protocol amendment. The primary endpoint was composite complete response (complete response, complete response with incomplete platelet recovery, or complete response with incomplete neutrophil recovery regardless of platelets). Response was assessed in all patients (as-treated) who received at least one dose of guadecitabine. We present the final analysis, although at the time of the database lock, 15 patients were still in follow-up for overall survival. This study is registered with ClinicalTrials.gov, number NCT01261312.

Findings

Between Aug 24, 2012, and Sept 15, 2014, 107 patients were enrolled: 54 on the 5-day schedule (26 randomly assigned to 60 mg/m2 and 28 to 90 mg/m2) and 53 were assigned to the 10-day schedule. Median age was 77 years (range 62–92), and median follow-up was 953 days (IQR 721–1040). All treated patients were assessable for a response. The number of patients who achieved a composite complete response did not differ between dose groups or schedules (13 [54%, 95% CI 32·8–74·4] with 60 mg/m2 on the 5-day schedule; 16 [59%; 38·8–77·6] with 90 mg/m2 on the 5-day schedule; and 26 [50%, 35·8–64·2] with 60 mg/m2 on the 10-day schedule). The most frequent grade 3 or worse adverse events, regardless of relationship to treatment, were febrile neutropenia (31 [61%] of 51 patients on the 5-day schedule vs 36 [69%] of 52 patients on the 10-day schedule), thrombocytopenia (25 [49%] vs 22 [42%]), neutropenia (20 [39%] vs 18 [35%]), pneumonia (15 [29%] vs 19 [37%]), anaemia (15 [29%] vs 12 [23%]), and sepsis (eight [16%] vs 14 [27%]). The most common serious adverse events, regardless of relationship to treatment, for the 5-day and 10-day schedules, respectively, were febrile neutropenia (27 [53%] vs 25 [48%]), pneumonia (14 [27%] vs 16 [31%]), and sepsis (eight [16%] vs 14 [27%]). 23 (22%) patients died because of adverse events (mainly from sepsis, eight [8%]; and pneumonia, five [5%]); four deaths were from adverse events deemed treatment-related (pneumonia, two [2%]; multiorgan failure, one [1%]; and sepsis, one [1%], all in the 10-day cohort).

 Interpretation

More than half of older treatment-naive patients with acute myeloid leukaemia achieved a composite complete response with guadecitabine at all drug doses and schedules investigated, with tolerable toxicity. The recommended guadecitabine regimen for this population is 60 mg/m2 in a 5-day schedule. A phase 3 study in this patient population is ongoing (NCT02348489) to assess guadecitabine 60 mg/m2 in a 5-day schedule versus standard of care.

References
  1. Kantarijian H.M., Roboz G. J. et al. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. Lancet Oncol. 2017 Aug 24. DOI: 10.1016/S1470-2045(17)30576-4. [Epub ahead of print].
  2. Ferrara F. Guadecitabine: a new therapeutic option for acute myeloid leukaemia? Lancet Oncol. 2017 Aug 24. DOI: 10.1016/S1470-2045(17)30614-9. [Epub ahead of print].